- Home
- MMV vs NRXS Comparison
MMV vs NRXS Comparison
Compare MMV & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMV
- NRXS
- Stock Information
- Founded
- MMV 2015
- NRXS 2011
- Country
- MMV China
- NRXS United States
- Employees
- MMV N/A
- NRXS N/A
- Industry
- MMV Blank Checks
- NRXS
- Sector
- MMV Finance
- NRXS
- Exchange
- MMV Nasdaq
- NRXS Nasdaq
- Market Cap
- MMV 18.8M
- NRXS 20.9M
- IPO Year
- MMV N/A
- NRXS 2023
- Fundamental
- Price
- MMV $0.49
- NRXS $3.16
- Analyst Decision
- MMV
- NRXS
- Analyst Count
- MMV 0
- NRXS 0
- Target Price
- MMV N/A
- NRXS N/A
- AVG Volume (30 Days)
- MMV 149.6K
- NRXS 5.8K
- Earning Date
- MMV 01-01-0001
- NRXS 08-09-2024
- Dividend Yield
- MMV N/A
- NRXS N/A
- EPS Growth
- MMV N/A
- NRXS N/A
- EPS
- MMV N/A
- NRXS N/A
- Revenue
- MMV $9,008,244.00
- NRXS $2,267,053.00
- Revenue This Year
- MMV N/A
- NRXS $383.16
- Revenue Next Year
- MMV N/A
- NRXS N/A
- P/E Ratio
- MMV N/A
- NRXS N/A
- Revenue Growth
- MMV N/A
- NRXS N/A
- 52 Week Low
- MMV $0.41
- NRXS $1.80
- 52 Week High
- MMV $2.05
- NRXS $5.24
- Technical
- Relative Strength Index (RSI)
- MMV 38.30
- NRXS 44.49
- Support Level
- MMV $0.46
- NRXS $2.93
- Resistance Level
- MMV $0.54
- NRXS $3.25
- Average True Range (ATR)
- MMV 0.05
- NRXS 0.10
- MACD
- MMV -0.00
- NRXS -0.01
- Stochastic Oscillator
- MMV 31.94
- NRXS 13.85
About MMV MultiMetaVerse Holdings Limited
MultiMetaVerse Holdings Ltd is an animation and entertainment company. It is devoted to establishing an open community for its global users comprised of animation viewers, game players, and content creators and to providing high-quality and immersive entertainment experiences by way of original content, user-generated content, and professional user-generated content.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).